echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Biotech TIGIT monoclonal antibody was approved for clinical use

    Biotech TIGIT monoclonal antibody was approved for clinical use

    • Last Update: 2021-08-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 7, the official website of CDE showed that Biotec TIGIT monoclonal antibody BAT6021 was approved for clinical use


    According to Biotech's prospectus, BAT6021 is an afucosylation-modified mAb drug candidate, targeting TIGIT for the treatment of tumors


    Biotech's pipeline under development

    From: Prospectus

    The Insight database shows that there are currently 9 clinical TIGIT-related projects in China


    TIGIT target domestic competition details

    From the Insight library (http://db.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.